SELLAS Life Sciences (SLS) Payables (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Payables of $3.6 million for Q1 2026, down 3.27% year-over-year from $3.8 million in Q1 2025, and up 23.24% quarter-over-quarter from $2.9 million in Q4 2025.
SELLAS Life Sciences (SLS) Payables (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Payables for 17 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 3.27% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 3.27% YoY), while the FY2025 annual figure was $2.9 million, down 15.77% from the prior year.
- Payables climbed to $3.6 million in Q1 2026 per SLS's latest filing, from $2.9 million in the prior quarter.
- Across five years, Payables topped out at $7.4 million in Q1 2024 and bottomed at $2.1 million in Q3 2022.
- Historically, Payables has averaged $3.9 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2024 — Payables surged 139.01% — and 2025, when it plunged 49.31%.
- SELLAS Life Sciences' Payables stood at $3.4 million in 2022, then jumped by 67.98% to $5.6 million in 2023, then slumped by 37.93% to $3.5 million in 2024, then fell by 15.77% to $2.9 million in 2025, then increased by 23.24% to $3.6 million in 2026.
- Business Quant data shows SLS's Payables at $3.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.09 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 3.76 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | 4.55 Mn |
| Jun 30, 2024 | 6.33 Mn |
| Mar 31, 2024 | 7.41 Mn |
| Dec 31, 2023 | 5.64 Mn |
| Sep 30, 2023 | 4.34 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Mar 31, 2023 | 3.10 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 3.34 Mn |
| Mar 31, 2022 | 2.84 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 2.55 Mn |